These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34590235)

  • 1. Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study.
    Tookes H; Ucha J; Rodriguez AE; Suarez E; Alonso E; Metsch LR; Feaster DJ; Bartholomew TS; Hoffman KA; Korthuis PT
    J Behav Health Serv Res; 2022 Apr; 49(2):240-251. PubMed ID: 34590235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial.
    Hoffman KA; Baker R; Kunkel LE; Waddell EN; Lum PJ; McCarty D; Korthuis PT
    BMC Health Serv Res; 2019 Nov; 19(1):862. PubMed ID: 31752905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.
    Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE
    Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England.
    Romo E; Rudolph AE; Stopka TJ; Wang B; Jesdale BM; Friedmann PD
    Addict Sci Clin Pract; 2023 Jan; 18(1):2. PubMed ID: 36597153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syringe access and health harms: Characterizing "landscapes of antagonism" in California's Central Valley.
    Syvertsen JL; Pollini RA
    Int J Drug Policy; 2020 Jan; 75():102594. PubMed ID: 31775079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida.
    Bartholomew TS; Feaster DJ; Patel H; Forrest DW; Tookes HE
    J Subst Abuse Treat; 2021 Aug; 127():108344. PubMed ID: 34134863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of machine learning algorithms for localized syringe services program policy implementation - Florida, 2017.
    Bartholomew TS; Tookes HE; Spencer EC; Feaster DJ
    Ann Med; 2022 Dec; 54(1):2137-2150. PubMed ID: 35900201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection Behaviors and Use of Syringe Service Programs over Time among People Who Inject Drugs in Baltimore, Maryland.
    German D; Glick JL; Yenokyan K; Genberg B; Sawyer A; Gribbin M; Flynn C
    Subst Use Misuse; 2024; 59(5):651-664. PubMed ID: 38115628
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Were Needles Everywhere?: Differing Views on Syringe Waste and Disposal Associated With Needs-Based Syringe Services Programs Among Community Partners and Persons Who Inject Drugs.
    Hershow RB; Love Pieczykolan L; Worthington N; Adams M; McDonald R; Wilson S; McBee S; Balleydier S; Curran KG
    Subst Use Misuse; 2024; 59(8):1174-1181. PubMed ID: 38509704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated with Sterile Syringe Acquisition among People Who Inject Drugs in West Virginia.
    Allen ST; Mazhnaya A; O'Rourke A; White RH; Wedlock P; Grieb SM; Kilkenny ME; Walls M; Sherman SG
    Subst Use Misuse; 2021; 56(12):1776-1784. PubMed ID: 34311667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of syringe services program closure on the risk of rebound HIV outbreaks among people who inject drugs: a modeling study.
    Zang X; Goedel WC; Bessey SE; Lurie MN; Galea S; Galvani AP; Friedman SR; Nosyk B; Marshall BDL
    AIDS; 2022 May; 36(6):881-888. PubMed ID: 35212666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL.
    Bartholomew TS; Onugha J; Bullock C; Scaramutti C; Patel H; Forrest DW; Feaster DJ; Tookes HE
    Harm Reduct J; 2020 Jun; 17(1):40. PubMed ID: 32522201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Infection and HIV-Associated Behaviors Among Persons Who Inject Drugs - 23 Metropolitan Statistical Areas, United States, 2018.
    Handanagic S; Finlayson T; Burnett JC; Broz D; Wejnert C;
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(42):1459-1465. PubMed ID: 34673746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.
    Frost MC; Sweek EW; Austin EJ; Corcorran MA; Juarez AM; Frank ND; Prohaska SM; LaKosky PA; Asher AK; Broz D; Jarlais DCD; Williams EC; Glick SN
    AIDS Behav; 2022 Jan; 26(1):57-68. PubMed ID: 34110506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
    Bartholomew TS; Tookes HE; Bullock C; Onugha J; Forrest DW; Feaster DJ
    Int J Drug Policy; 2020 Apr; 78():102716. PubMed ID: 32146348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.